Physician profile
Reginald Kapteyn
NPI 1366601536
$11,248.57
in general payments reported to CMS, 2019-2025
31 companies · $2,480 in 2025
The $2,480 reported for 2025 was more than what 95% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,793 · 2020: $50.26 · 2021: $182 · 2022: $127 · 2023: $3,282 · 2024: $1,334 · 2025: $2,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,805 · Travel and Lodging: $2,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,805.11 |
| Travel and Lodging | $2,290.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hydrocision, INC. | $3,525.79 | 2019-2024 | Tenjet |
| Medtronic, INC. | $3,243.36 | 2023-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Boston Scientific Corporation | $1,799.09 | 2023-2025 | Intracept, Wavewriter Alpha Prime 16, Intracept Rf Probe |
| Abbott Laboratories | $307.74 | 2023-2024 | Proclaim, Eterna |
| Sonex Health, INC. | $299.63 | 2021-2024 | Sx-One Microknife |
| Mml US, INC. | $242.87 | 2024-2025 | Reactiv8 |
| Spr Therapeutics, INC | $226.22 | 2023-2025 | Sprint Pns System |
| Nevro Corp. | $198.75 | 2023-2024 | Senza |
| Vertex Pharmaceuticals Incorporated | $169.72 | 2025 | |
| Globus Medical, INC. | $149.47 | 2025 | Senza |
| Curonix LLC | $133.52 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Saluda Medical Americas, INC. | $132.33 | 2025 | Evoke |
| Allergan, INC. | $106.72 | 2019-2022 | |
| Pacira Therapeutics, INC. | $76.81 | 2019-2021 | |
| Vertiflex, INC. | $74.68 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $73.56 | 2019 | |
| Collegium Pharmaceutical, INC. | $66.51 | 2023-2024 | Xtampza |
| Si-Bone, INC. | $47.82 | 2019-2023 | |
| Averitas Pharma INC. | $46.65 | 2023-2024 | Qutenza |
| Nalu Medical, INC. | $44.20 | 2024 | Nalu Neurostimulation System |
| Avanos Medical | $40.51 | 2019 | |
| Abbvie INC. | $39.15 | 2022-2025 | |
| Stimwave Technologies Incorporated | $36.34 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $35.84 | 2022 | |
| Stryker Corporation | $34.16 | 2024 | Mild Device Kit |
| Medtronic USA, INC. | $23.54 | 2019 | |
| Pfizer INC. | $21.30 | 2023 | |
| Fidia Pharma USA INC. | $16.70 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.50 | 2020 | |
| Bioventus LLC | $12.03 | 2020 | |
| Amgen INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$35,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reginald Kapteyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.